The ongoing shuffle-and-cut at AstraZeneca has two U.S. higher-ups headed for the exit. As the Washington Business Journal reports, the company's new specialty care unit will lose its top executive, Scott Carmer, and finance chief, Tim Gray.
The FDA has accepted an NDA for Nektar Therapeutics' naloxegol, triggering a $70 million milestone payment from partner AstraZeneca.
AstraZeneca and its stilted R&D division aren't scheduled to move to Cambridge, U.K., until 2016, but the drugmaker can't wait to settle in at what it calls "one of the world's preeminent biosciences hotspots," planning to send an advance team of scientists to plant some collaborative seeds.
New pay-for-delay lawsuits are popping up around the country. Endo Pharma and Actavis have been named, as has AstraZeneca, Teva, Ranbaxy and Dr. Reddy's. And with the U.S. Supreme Court having defined its position this year, the pay-for-delay legal issue is being litigated under a whole new set of rules.
In 2011, AstraZeneca jettisoned about 1,200 employees when it shuttered its R&D shop near Nottingham, U.K., but now the city is home to 22 life sciences startups launched by the drugmaker's former workers.
New rules for prescribing statin drugs could double the number of people taking them--or not. They could help AstraZeneca pump up sales of its high-powered Crestor--or not. What they will do--most likely--is undercut Merck's cholesterol drugs Vytorin and Zetia, along with AbbVie's fenofibrate-based lipid meds TriCor and Trilipix.
Injectable drug delivery specialist Unilife joined forces with AstraZeneca's MedImmune this week to use Unilife's wearable devices with MedImmune's line of large molecules, putting both companies on the leading edge of a potentially profitable market.
AstraZeneca has decided that the experience it has at its plant in Macclesfield, England, which has produced its prostate cancer drug Zoladex for 25 years, make it the best location for its new £120 million ($190 million) plant to manufacture the sterile drug.
AstraZeneca's prostate cancer drug Zoladex remains among the drugmaker's top products. The company decided it needs more production capacity, so it will spend £120 million ($190 million) on a new facility at its complex in Macclesfield, England.
Last week, AstraZeneca succinctly disclosed that Department of Justice investigators are digging into its data on the blood thinner Brilinta. Now, European regulators are adding their shovels to the effort. If they're not satisfied with their findings, AstraZeneca's hopes for pumping up Brilinta sales could be in vain.